^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

Published date:
02/13/2012
Excerpt:
A 62-year-old, non-smoking female with adenocarcinoma of the right lung...Her tumor cells had increased EGFR/HER1 copy number, as assessed by FISH, as well as mutations in the EGFR kinase domain (exon 21: p.Ala859Thr) and in HER2 (exon 20: p.Gly776Leu)....patient was treated with afatinib (50 mg/day). Within 2 weeks, the cervical soft-tissue swelling decreased with marked improvement in her general condition (ECOG PS: 1). On Day 15, a metabolic response was observed in a PET-CT scan...
DOI:
10.1016/j.lungcan.2012.01.008